Study on the Hypoglycemic and Anti-inflammatory Effects of Cyclocarya paliurus Leaf-Extract

• Main Authors: CHEN,YOU-JU, 陳佑儒
• Other Authors: SHIEN,DEN-EN
• Format: Others
• Language: zh-TW
• Published: 2019
• Online Access: http://ndltd.ncl.edu.tw/handle/eu2wqh

碩士 === 大仁科技大學 === 藥學系碩士班 === 107 === Diabetes is a metabolic disease. Diabetes is characterized by the blood sugar of the patient is over the standard value for a long time. At least 150 million people worldwide suffer from diabetes. This incident shows that diabetes has seriously threatened the health of the people. Currently, about 90% of patients with diabetes are classified as type 2 diabetes. In recent years, studies have shown that type 2 diabetes causes inflammatory factors such as TNF-α, IL-6 and IL-1β...etc, which produce an inflammatory response that in turn causes insulin resistance. In the normal insulin signaling pathway, insulin binds to the insulin receptor and phosphorylates IRS1/2/3, PI3K and Akt. Eventually, GLUT4 is displaced onto the cell membrane and glucose is transported into the cell for utilization. PTP1B is a negative regulator of the insulin signaling pathway. PTP1B exacerbates hyperglycemia in the case of insulin resistance. Cyclocarya paliurus is commonly used as a clinical hypoglycemic agent in traditional Chinese medicine. It is rich in a variety of chemical ingredients, which not only can lower the three highs, oxidative stress and inflammatory response. This study focused on the effects of Cyclocarya paliurus leaf-extract (CPE) on the regulation of blood sugar and inflammation. First of all discovered by the test of RINm5F cell proliferation, after addition CPE 50.0 μg/mLand 24 hours, the optimal proliferation effect (71.0%) was achieved. In the mouse of blood sugar regulation test, after continuous administration of CPE for 28 days, The CPE medium dose group (200.0 mg/mL) significantly increased Total-protein (14.99%), decreased Glucose AC (65.48%), Triglyceride (28.33%) and Total-cholesterol (31.32%); increased the performance of IRS2 (108.43%), Akt1/2/3 (93.18%) and GLUT4 (140.22%), and significant statistical differences (p<0.05) compared with the STZ group. In addition, compared with the TPA group, the reduction of ear edema was 26.9 % and 27.2 % respectively, after administration of high dose CPE (25.0 mg/mL) for 12 and 24 hours in the anti-inflammatory experiment of mice. In addition, compared with the TPA group, the reduction of ear edema was 26.9 % and 27.2 % respectively, after administration of high dose CPE ( 25.0 mg/mL ) for 12 and 24 hours in the anti-inflammatory experiment of mice, and the inhibitory effect is better than the positive control Medicine (Indomethacin). In the PTP1B inhibition test, the PTP1B content decreased with the higher dose. At the high dose of CPE (5.0 mg/mL), it has the lowest concentration (0.001 ± 0.08 nmol). It shows that the higher CPE concentration has the better inhibitory effect. Based on the above experimental results, CPE can improve the hyperglycemia of diabetic patients by regulating biochemical indicators and enhancing the transmission of insulin signals, and reduce the insulin resistance of patients by anti-inflammatory reaction. In addition, it can enhance insulin signal transmission by inhibiting the action of PTP1B. CPE can regulate blood sugar in many ways, which is beneficial to the recovery of diabetes.